Greater China News
Sanofi, Teva sign deal worth $1.5 billion to co-develop blockbuster inflammatory bowel disease drug
French drug maker Sanofi has announced that it is teaming up with Israel-based Teva Pharmaceuticals to co-develop an anti-TL1A therapeutic for inflammatory bowel disease in a deal worth up to $1.5 billion.
上海浦东新区：推动产业与资本对接 打造生物医药世界级产业集群
上证报中国证券网讯 上海市政府今日举办新闻发布会，介绍2023上海国际生物医药产业周的有关情况。上海市浦东新区副区长吴强在会上表示，浦东新区将通过更高水平的科技创新和资本要素融合，助力浦东打造生物医药世界级产业集群。主要举措包括：
Precision Neuroscience wins FDA breakthrough nod for BCI, buys factory in Texas
Precision Neuroscience announced today that its brain-computer interface (BCI) technology won FDA breakthrough device designation.
Sanofi Is Exploring Acquisition of Cancer Drugmaker Mirati
French pharmaceutical firm Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc., according to people familiar with the matter.
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion.
Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments
“ALSP has long been interested in helping to drive biopharma innovation emerging in Singapore,” said Alice Chen, Executive Vice President at ALSP and Automera board member.
Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the U.S. Food and Drug Administration (FDA) has granted Tetra Therapeutics Inc. (hereafter "Tetra"), a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational treatment being studied for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.
Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products
Triastek, Inc. ("Triastek") today announced the completion of a USD 20.4 million Pre-C financing round. This milestone marks a significant step in the advancement of Triastek's innovative solutions for drug development and manufacturing.
AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics
AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash. The anticipated transaction will materially expand Alfasigma’s gastrointestinal and hepatology portfolio and its presence in the U.S. market.
